Why DePuy Synthes’ Gemtrack deal could reshape navigation in hip, knee and shoulder surgery
DePuy Synthes wants to remove a robotics bottleneck. Its Gemtrack deal could change joint surgery navigation if regulators agree.
GHO Capital and CBC Group deal signals a bigger private capital push into life sciences
GHO Capital and CBC Group are creating a $21bn healthcare investor. Find out what it means for pharma, medtech and life sciences funding.
Portable MRI in emergency departments: What Hyperfine’s PRIME data changes
Find out how Hyperfine’s PRIME study could reshape emergency brain imaging with faster bedside portable MRI access.
Align Technology is betting $200m on Hyderabad. Here’s what changes next
Align needs growth and supply-chain efficiency. Its Hyderabad factory could turn India into a larger digital dentistry manufacturing base.
Medtronic’s SPR Therapeutics deal signals a sharper move into earlier chronic pain intervention
Chronic pain care needs non-opioid options. Medtronic’s SPR Therapeutics deal tests whether temporary PNS can scale beyond niche adoption.
Is Avvio Medical building the next outpatient frontier in kidney stone and ureteral stone therapy?
Ureteral stones need faster care. Avvio Medical’s outpatient device tests whether microbubble lithotripsy can ease OR bottlenecks.
HistoSonics just cleared a major Asia hurdle. Could histotripsy move beyond liver tumors next?
HistoSonics cleared Taiwan, but the bigger test is whether histotripsy can scale from liver tumors into broader oncology use.
Can Fujifilm’s EB-710US simplify lung cancer staging procedures in the United States?
EBUS imaging is clinically valuable, but workflow remains messy. Fujifilm’s EB-710US tests whether simpler design can change adoption.
Why BlueWind Medical’s $47.8m raise matters for the next phase of UUI treatment
UUI devices have clinical momentum. BlueWind Medical’s next challenge is proving Revi can scale through access, reimbursement, and workflow adoption.
Is Butterfly Medical’s prostate retraction device the next challenger in minimally invasive BPH treatment?
BPH care needs options beyond pills and surgery. Butterfly Medical’s $21m raise puts its reversible prostate implant in the spotlight.